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ARTICLE
Blood substitution therapy rescues the brain of
mice from ischemic damage
Xuefang Ren 1,2,3,4✉, Heng Hu1,3,5, Imran Farooqi1,6 & James W. Simpkins1,3,7✉
Acute stroke causes complex, pathological, and systemic responses that have not been
treatable by any single medication. In this study, using a murine transient middle cerebral
artery occlusion stroke model, a novel therapeutic strategy is proposed, where blood
replacement (BR) robustly reduces infarctions and improves neurological deficits in mice. Our
analyses of immune cell subsets suggest that BR therapy substantially decreases neutrophils
in blood following a stroke. Electrochemiluminescence detection demonstrates that BR
therapy reduces cytokine storm in plasma and ELISA demonstrates reduced levels of matrix
metalloproteinase-9 (MMP-9) in the plasma and brains at different time points post-stroke.
Further, we have demonstrated that the addition of MMP-9 to the blood diminishes the
protective effect of the BR therapy. Our study is the first to show that BR therapy leads to
profoundly improved stroke outcomes in mice and that the improved outcomes are mediated
via MMP-9. These results offer new insights into the mechanisms of stroke damage.
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A stroke remains a major cause of morbidity and mortalityglobally1. Current treatments for acute stroke includethrombolytic therapy through the administration of tissue
plasminogen activator and the surgical removal of the clot.
However, these methods have limited time windows. In the
clinical field of stroke, the mantra is “time is brain,” because
infarct evolves every minute following a stroke.
A stroke is more than just a disruption of blood flow to the
brain; stroke pathophysiology is a progressive and systemic
response to brain injury2. Dynamic breaches of the blood–brain
barrier (BBB) has been observed in experimental stroke animal
models3,4 and stroke patients5. Following BBB disruption after
ischemic stroke, a pathological and systemic reaction may be
initiated. A hyperinflammatory condition, including an increase
in inflammatory cells, cytokines, and chemokines in circulating
blood has been documented in stroke6. Activated neutrophils
secret proteinases such as matrix metalloproteinase-9 (MMP-9),
which may cause BBB leakage, extracellular matrix degradation,
and evolution of cerebral ischemia7. MMP-9 also interacts with
chemokines8 and cytokines9–11, causing a further cascade of post-
ischemic cerebral inflammation that leads to degeneration in
brain tissue and exacerbates stroke outcomes.
In this study, using a murine transient middle cerebral artery
occlusion (tMCAO) stroke model, we present a therapeutic
strategy for stroke—a blood replacement (BR) that substitutes
stroke mouse blood with whole blood obtained from naive,
healthy donor mice. We have demonstrated that the BR per-
formed at 6.5~7 h following a stroke robustly reduces infarct
volume and improves neurological deficits. Following the treat-
ment, we demonstrate that the BR therapy significantly reduces
the cytokine storm in the plasma. In addition, flow cytometry and
enzyme-linked immunosorbent assay (ELISA) have demonstrated
substantially reduced neutrophils and decreased levels of MMP-9
in the blood and brains of stroke mice, which received whole
blood obtained from naive donor mice. Further, addition of
MMP-9 in blood diminishes therapeutic effects of the BR therapy.
These results reveal a possible therapy of using blood for brain
protection from a stroke.
Results
The BR therapy improves stroke outcomes in post-stroke mice.
Using an experimental stroke animal model of tMCAO, we
demonstrated that infarction evolves following a 90min tMCAO
and reperfusion (Supplementary Fig. 1). We determined larger
infarction from stroke mice at 23 h compared to 6 h, indicating that
the injury evolves over time after removals of filaments in MCA-
occluded stroke mice. We have also demonstrated that stroke alters
cellular profiles in blood following a 90min tMCAO and ischemic
reperfusion in mice (Supplementary Fig. 2). We found that absolute
cell numbers of neutrophils (Gr1+), monocytes, CD4+ cells, CD8+
cells, and NK1.1+ cells were significantly increased but CD19+ B
cells were decreased at 6 h post stroke compared to controls. The
data suggest that blood might play a critical role in the evolution of
a stroke and the injured brain may be rescued if a blood-based
strategy is used during a critical time window.
To determine the role of blood in stroke, we conducted a
dose–response experiment of BR on stroke outcomes using a
murine tMCAO model (Fig. 1a). Before the BR, we recorded global
cerebral blood flow (CBF) changes at four time points as follows:
prior to tMCAO, at 1 min post tMCAO, at 5 min post reperfusion,
and prior to the BR in mice using a Laser Speckle Imager. We
confirmed that the MCAO reduced 70~80% relative CBF (ratio of
CBF in the right MCA territory : CBF in the left MCA territory) at
the post-tMCAO time point and reperfusion fully recovered the
relative CBF at 5min post-reperfusion measurements and prior to
the BR in all stroke mice; however, no significant differences were
detected among randomized groups of mice (Supplementary
Fig. 3). Then, we replaced stroke mice blood with different doses of
whole blood obtained from naive donor mice at 6.5~7 h after
ischemia. Although the data demonstrated that 250 and 500 µl of
the blood robustly reduced stroke infarction in the cortex,
striatum, and hemisphere compared to sham control group,
500 µl of the blood had a greater protection in brain damage
following a stroke (Fig. 1b, c). Interestingly, neurological deficits
were significantly improved in the BR groups compared to the
control group (Fig. 1d). Furthermore, we performed an Evans blue
extravasation assay and demonstrated that 250 and 500 µl of blood
protected the BBB, as evidenced by less Evans blue extravasation in
ischemic hemispheres (Fig. 1e, f). However, the BR therapy did not
change physiology parameters in the blood of stroke mice
(Supplementary Table 1).
To further confirm the pathological changes in stroke brains,
we conducted cresyl violet staining (Fig. 2a) and hematoxylin and
eosin (H&E) staining (Fig. 2b). At high magnification, we
observed typical pyknotic neurons or dark neurons in selected
cortex and striatum areas in control mice following 90 min
tMCAO at 23 h post stroke. Interestingly, morphologically intact
neurons were broadly seen in similar brain areas of mice with the
BR therapy. The degenerating neurons were broadly detectable by
terminal deoxynucleotidyl transferase dUTP nick end labeling
(TUNEL) staining (Fig. 2d, positive staining in brown) and
Fluora-Jade C (Fig. 2d, positive staining in fluorescent green)
staining in control mice but only a few in BR-treated mice. The
data clearly demonstrated that the BR therapy prevent brain cells
from ischemic damage.
Then we ask whether the BR is neuroprotective or just delays
the eventual infarct evolution to its final state. We treated stroke
mice with the BR therapy and then evaluated outcomes at 72 h
post stroke (Fig. 3). Infarction did not further evolve in BR
therapy-treated stroke mice, while matured infarction was
observed in control mice by TTC staining (Fig. 3b, c). The BR
therapy-treated mice had significantly better functional outcomes
than control mice from post-stroke day 1 through day 3 (Fig. 3d).
Taken together, these data suggest that BR therapy results in a
profound protection in ischemic brains and offers a therapeutic
effect for stroke.
We next sought to understand whether blood transfusion alone
or blood withdrawal alone protects stroke outcomes. The mice in
both blood transfusion alone and blood withdrawal alone groups
had large infarction and high mortalities (six of nine mice died in
each group within 23 h of stroke) (Supplementary Fig. 4),
suggesting that transfusion of blood and withdrawal of blood
are both required for BR therapy for stroke treatment.
To further assess the effects of blood on outcomes in stroke, we
transfused 500 µl of whole blood obtained from stroke mice, but
this cohort of mice had larger infarct volumes and a higher
mortality (six of nine recipient stroke mice died within 23 h of
stroke, mortality is 66.7%) than the cohort of mice replaced with
blood obtained from naive donor mice (0 of six mice died)
(Supplementary Fig. 5). Fisher’s exact test determined 90% power
of the mortality differences between whole blood obtained from
stroke mice and naive donor mice. The data suggest that blood
from healthy donors is important when applying BR therapy in
stroke.
The BR therapy alters inflammatory responses in the periphery
of stroke mice. It is now accepted that inflammation and the
immune system are critical in acute stroke damage12,13. As shown
in Supplementary Fig. 2, stroke significantly changed cellular
profiles in the blood of mice following tMCAO. To further
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Fig. 1 Blood replacement improves stroke outcomes. a Experimental design. Mice (8~12 months old males) underwent tMCAO for 90min. The occlusion
and reperfusion were confirmed by a laser speckle imager (LSI). Mice were randomized into three groups: sham control, 250 µl, or 500 µl of blood from
healthy donors (3~6 months old). Blood was transfused into stroke mice at 6.5~7 h post stroke. The same volume of blood was withdrawn from the
recipient stroke mice during blood transfusion. Brain infarct volumes were measured at 23 h after ischemia induction. BBB permeability was evaluated at 1 h
post blood replacement (BR). b BR reduced infarct volume in the cortex, striatum, and total hemisphere dose dependently. Sham control (circles, n= 6),
250 µl group (squares, n= 6), or 500 µl group (triangles, n= 6) of blood from healthy donors. c Representative triphenyltetrazolium chloride (TTC)-
stained coronal brain sections used for infarction analyses. d Neurological deficits were significantly improved in the BR group. Sham control (circles, n=
8), 250 µl group (squares, n= 6), or 500 µl group (triangles, n= 6) of blood from healthy donors. e BR reduced Evans blue extravasation in the brain dose
dependently. Sham control (circles, n= 6), 250 µl group (squares, n= 6), or 500 µl group (triangles, n= 6) of blood from healthy donors. f Representative
coronal brain sections showing Evans blue extravasation. Data were presented as means ± SEM. One-way ANOVA followed by post hoc Fisher’s





Fig. 2 Blood replacement protects the brain from cell death in stroke mice. Microscopic images of brain tissue taken from stroke mice underwent
tMCAO for 90min followed by 22.5 h reperfusion. The blood replacement (BR) group received 500 µl of blood from healthy donors (3~6 months old) at
6.5~7 h post stroke. a The Cresyl violet staining, b H&E staining, c TUNEL staining counterstained with Methyl Green, and d Fluoro-Jade C staining were
performed on paraffin embedded brain slices. Red rectangles indicate the magnified areas evaluated under ×40 magnification. Both the cortex and striatum
were evaluated. Experiments were repeated five times with similar results and images were presentative of one mouse from five mice per group. Scale bars
= 20 µm.
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investigate how BR therapy affects the cellular populations in the
blood of stroke mice, we assessed cellular subsets in the blood of
recipient stroke mice at three time points—prior to BR, during
BR, and at 1 h post BR. The recipient stroke mice received 500 µl
of whole blood obtained from either naive donors or stroke mice
and additional control group received 500 µl of plasma obtained
from naive donors (Fig. 4a). In randomized groups, total white
blood cell counts were not significantly different prior to the BR
(Fig. 4b). Interestingly, whole blood obtained from naive donors
resulted in significantly lower total leukocyte numbers and neu-
trophils during BR and at 1 h post BR in the blood of recipient
stroke mice compared to whole blood obtained from stroke mice
or plasma obtained from naive donors. There were substantially
more total leukocytes and neutrophils but less CD19+ B cells in
the blood of recipient stroke mice that received whole blood from
the stroke mice group and plasma from the naive donor group
than the mice that received whole blood from naive donor group.
There were no significant changes in monocytes CD4+ cells, CD8
+ cells, and NK1.1+ cells in blood of recipient stroke mice among
plasma from naive donor group, whole blood from naive donor
group, and whole blood from the stroke mice group (Fig. 4c–l).
In line with the changes of cell numbers in blood of stroke
mice, the levels of proinflammatory cytokines and the chemokine,
CXCL1, in plasma were also altered (Fig. 5). The data
demonstrated that BR therapy significantly reduced the levels of
proinflammatory cytokines interleukin (IL)-1β, IL-6, TNF-α,
and the chemokine, CXCL1, at 8 h post stroke and further
reduced IL-6, IFN-γ, and TNF-α at 23 h post stroke. CXCL1
known as a neutrophil-activating protein is responsible for
neutrophil chemotaxis14. The significant change of CXCL1 at
early stroke suggests that neutrophils might have played an
important role in stroke and involved in BR therapy.
The BR therapy alters cerebral leukocyte invasion in stroke
mice. Leukocytes are the major effectors of inflammatory damage
in stroke brains. Among them, neutrophils and macrophages are
early responders to a stroke. To investigate whether BR therapy
affects central nervous system (CNS) inflammatory infiltration,
we designed a study to analyze leukocyte invasion in the hemi-
spheres of stroke mice (Fig. 6a). The BR therapy significantly
reduced total absolute cell numbers in ischemic hemispheres at 8
and 23 h post stroke (Fig. 6b, c). To further investigate how BR
therapy affects leukocyte composition in the brain after stroke,
numbers of infiltrating Gr1+ neutrophils, and CD11b+CD45high
macrophages, CD3+ T cells and CD19+ B cells were assessed by
flow cytometry. At both time points, the accumulation of neu-
trophils and macrophages was significantly less in the affected
hemispheres of BR-treated stroke mice compared with control
stroke mice (Fig. 6d–i). These data suggest that BR therapy can
reduce CNS inflammatory responses to a stroke.
MMP-9 is involved in the BR therapeutic in stroke. MMP-9 is
one of proteinases that is expressed by neutrophils and
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Fig. 3 Blood replacement therapy protects infarct evolution. a Experimental design. Mice underwent tMCAO for 90min. The occlusion and reperfusion
were confirmed by laser speckle imager (LSI). Mice were randomized into two groups: sham controls and the blood replacement (BR) group receiving
500 µl of blood from healthy donors (3~6 months old). Blood was transfused into stroke mice at 6.5~7 h post stroke. The same volume of blood was
withdrawn from the recipient stroke mice during blood transfusion. Brain infarct volumes were measured at 72 h after ischemia induction. b BR therapy
reduced infarct volume in the cortex, striatum, and total hemisphere. Sham controls (circles, n= 6) and the BR group (squares, n= 6). c Representative
TTC-stained coronal brain sections used for infarction analyses. d Neurological deficits were significantly improved in the BR group from day 1 to day 3.
Sham controls (circles, n= 10) and the BR group (squares, n= 6). Data were presented as means ± SEM; P-values were calculated using two-tailed
grouped analyses by Student’s t-test. Source data are provided as a Source Data file.
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Fig. 4 Blood replacement therapy alters cellular profiles in blood of stroke mice. a Experimental design. Mice (8 months old males) underwent tMCAO
for 90min. The occlusion and reperfusion were confirmed by laser speckle imager (LSI). Mice were randomized into three groups: receiving 500 µl of
plasma (circles, n= 6) from healthy donors, 500 µl of blood from healthy donors (squares, n= 6), and 500 µl of blood from stroke mice (90min tMCAO
followed by 4.5 h reperfusion) (triangles, n= 6). Blood was transfused into stroke mice at 6~8 h post stroke. The same volume of blood was withdrawn
from the recipient stroke mice during blood transfusion. Blood obtained from recipient stroke mice were analyzed at three time points: prior to blood
replacement (BR), during BR, and at 1 h post BR. b Total white blood cells were counted. c Representative flow cytometry images for neutrophils gated on
propidium iodide (PI)−CD45+CD11b+Gr-1+ populations and monocytes gated on PI-CD45+CD11b+Gr-1− populations. d Total neutrophil counts. e Total
monocyte counts. f Representative flow cytometry images for CD4+ cells gated on PI−CD45+CD4+ populations and CD8+ cells gated on PI−CD45+
CD8+ populations. g Total CD4+ cell counts. h Total CD8+ cell counts. i Representative flow cytometry images for CD19+ B-cells gated on PI−CD45+
CD19+ populations. j Total CD19+ B-cell counts. k Representative flow cytometry images for NK1.1+ cells gated on PI−CD45+NK1.1+ populations. l Total
NK1.1+ cell counts. Data were presented as means ± SEM. One-way ANOVA followed by post hoc Tukey’s test was used to determine the significance.
Source data are provided as a Source Data file.
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macrophages/monocytes15. MMP-9 is increased in the blood
within the first 2–6 h of stroke in patients, primates, and
rodents16–19. Given that BR therapy robustly reduced neutrophil
counts in the peripheral blood and significantly decreased the
infiltration of neutrophils and macrophages/monocytes in
ischemic hemispheres, it is important to further investigate how
MMP-9 is involved in BR-treated stroke. We designed a study to
evaluate the levels of MMP-9 in the plasma and brains following
tMCAO with the BR therapy compared to controls (Fig. 7a). We
demonstrated increased levels of MMP-9 in the plasma obtained
from tMCAO mice compared to controls at both 8 and 23 h post
stroke (Fig. 7b). Interestingly, BR therapy remarkably reduced the
levels of MMP-9 in the plasma of recipient stroke mice at both
early and late time points (Fig. 7b). However, MMP-2 was not
significantly changed between two groups at either time points
(Supplementary Fig. 6). We further evaluated the levels of MMP-
9 in the brains of these mice and demonstrated that BR therapy
significantly reduced the levels of MMP-9 in ischemic hemi-
spheres as well (Fig. 7c, d). These data are consistent with neu-
trophil changes in the periphery and CNS (Figs. 4 and 6), and
suggest that the decreased level of MMP-9 could be one of the
mechanisms by which the BR therapy improves stroke outcomes.
To further investigate the role of MMP-9 in the BR therapy in
stroke, we designed a study of using MMP-9-treated blood
compared to vehicle-treated blood for transfusion (Fig. 8a). To
compromise the high mortality from 90 tMCAO mice, a 60 min
tMCAO protocol is applied to the study. Interestingly, MMP-9-
treated blood significantly exacerbated stroke infarction and
worsened neurological deficits, whereas vehicle-treated blood
profoundly protected stroke outcomes following 60 min tMCAO
and 22 h reperfusion (Fig. 8c, d). The data clearly demonstrated
that MMP-9 diminished the therapeutic effects of BR in stroke
and suggested that a reduced level of MMP-9 could be one of the
important mechanisms used by the BR therapy in stroke.
Discussion
There may be multiple mechanisms occurring in BR. First, brain
antigens are released through the BBB openings and may activate
the immune system after stroke. Thus, the removal of blood from
stroke mice may reduce the levels of brain antigens in circulating
blood and alleviate the activation of immune system by brain
antigens. Second, the removal of blood from stroke mice may
diminish activated white blood cells and decrease many deleter-
ious signals, such as cytokines, chemokines, proteases, and pro-
teinases in circulating blood after stroke. Third, as observed in
patients with thrombotic thrombocytopenic purpura (TTP) dis-
ease, where the process of a blood transfusion may supply
nutrition factors for the TTP patients20, blood may also provide
oxygen and many other neuroprotective factors for stroke brains.
The mechanisms in the BR therapy for stroke may be more
complicated than one factor and it could be a challenge to address
all mechanisms here. We here demonstrate the BR therapy as an
effective therapeutic strategy for stroke treatment and elucidate
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Fig. 5 Blood replacement therapy alters cytokine panel in the plasma of stroke mice. Naive mice (8~12 months old males) serve as a control group
(circles, n= 6). Stroke mice (8~12 months old males) underwent tMCAO for 90min. The occlusion and reperfusion were confirmed by a laser speckle
imager. Stroke mice were then randomized into four groups: two groups being killed at 8 (squares, n= 6) and 23 h (diamonds, n= 6) post stroke; two
groups receiving blood replacement (BR) therapy and being killed at 8 (down-pointing triangles, n= 6) and 23 h (up-pointing triangles, n= 6) post stroke.
Then plasma was collected for the analyses of proinflammatory cytokine panel including IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IFN-γ, TNF-α, and the
chemokine, CXCL1. Data were presented as means ± SEM. One-way ANOVA followed by post hoc Fisher’s unprotected least-significant difference for
multiple comparison tests. Source data are provided as a Source Data file.
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The average total blood volume of a mouse is about 77~80 ml
kg−1 (0.077 ~ 0.080 ml gram−1)21. A mouse weighing 30 g would
therefore have a total blood volume of ~(77~80) ml kg−1 × 0.03
kg= 2.31 ~ 2.4 ml. Transfusion of 500 µl of blood is in <20% total
blood volume. This volume is translatable to human for blood
transfusion.
We have investigated the role of separated blood components
by the BR treatment in stroke. We conducted a study by testing
the effects of transfusion up to 500 µl of plasma while with-
drawing the same amount of blood from stroke mice. It has been
demonstrated that plasma from young mice ameliorates pathol-
ogy and cognition in a mouse model for Alzheimer’s disease22.
However, the results demonstrated that plasma transfusion did
not protect stroke outcomes as observed in whole-BR (Supple-
mentary Fig. 7). Plasma transfusion did not change cellular
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Fig. 6 Blood replacement therapy reduces cell infiltration into brains of stroke mice. a Experimental design. Mice (8~12 months old males) underwent
tMCAO for 90min. The occlusion and reperfusion were confirmed by a laser speckle imager (LSI). Recipient mice were then randomized into two groups: a
control group receiving sham surgery (white circles, n= 5) and a blood replacement (BR) group receiving 500 µl of blood from healthy donors (black
circles, n= 5). Blood was replaced into stroke mice at 6.5~7 h post stroke. The same volume of blood was withdrawn from the recipient stroke mice during
blood transfusion. Brains were perfused and analyzed at 8 and 23 h after ischemia induction. Blood from naive donors reduced numbers of total
inflammatory cells in ischemic hemispheres at b 8 and c 23 h post stroke. Representative flow cytometry images for neutrophils gated on propidium iodide
(PI)−CD45+CD11b+Gr-1+ populations and macrophages gated on PI−CD45+CD11b+Gr-1− populations in hemispheres at d 8 and e 23 h post stroke. Blood
from naive donors reduced numbers of absolute neutrophil counts in ischemic hemispheres at f 8 and g 23 h post stroke. Blood from naive donors reduced
numbers of absolute macrophage counts in ischemic hemispheres at h 8 and i 23 h post stroke. Data were presented as means ± SEM. One-way ANOVA
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Fig. 7 Blood replacement therapy reduces levels of MMP-9 in the plasma and brains in stroke mice. a Experimental design. Mice (8~12-month-old
males) underwent tMCAO for 90min. The occlusion and reperfusion were confirmed by a laser speckle imager (LSI). Stroke mice were then randomized
into two groups: a stroke only group and a blood replacement (BR) therapy group receiving 500 µl of blood from healthy donors. Blood was replaced into
stroke mice at 6.5~7 h post stroke. Brains were perfused and analyzed at 8 and 23 h after ischemia induction. b BR therapy reduced levels of MMP-9 in the
plasma at 8 and 23 h post stroke. Control (circles, n= 5), stroke mice analyzed at 8 h post stroke (squares, n= 5), stroke mice with BR therapy analyzed at
8 h post stroke (down-pointing triangles, n= 5), stroke mice analyzed at 23 h post stroke (diamonds, n= 5), stroke mice with BR therapy analyzed at 23 h
post stroke (up-pointing triangles, n= 5). The BR therapy reduced the levels of MMP-9 in ischemic hemispheres at c 8 and d 23 h post stroke. Data were
presented as means ± SEM. One-way ANOVA followed by post hoc Tukey’s tests. Stroke mice group (white circles, n= 5); stroke mice with BR therapy
group (black circles, n= 5). Source data are provided as a Source Data file.
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stroke mice donors (Fig. 4). The data also suggest that the ben-
eficial effects of the BR therapy is not simply due to a dilution of
blood in recipients. Transfusion of 500 µl of whole blood or
plasma is considered less than 20% of total blood volume into a
mouse. However, reduced neutrophil numbers (Fig. 4b) and the
levels of MMP-9 (Fig. 7b) by the BR therapy are far more than
20%. In addition, the data from proinflammatory cytokine and
chemokine panel (Fig. 7) also suggest that BR therapy does not
simply cause a dilution effect in the blood of stroke mice.
Therefore, we believe that BR therapy might reduce a cascade
response to a stroke that may be able to provide such a profound
protection in stroke brains.
It is important to identify key factors responsible for the
positive effects of a blood transfusion, because they may lead to
the development of cellular and molecule interventions with a
better efficacy. However, the role of specific cell types in produ-
cing ischemic brain damage remains a controversial topic and the
mechanisms of how inflammatory cells and their mediators are
involved in stroke-induced neuro-inflammation are still not fully
understood. In patients with ischemic stroke, the number of
circulating neutrophils rise within the first few hours of stroke
onset23. This increase is associated with stroke severity24, infarct
volume25, and worse functional outcomes26,27. Kleinschnitz
et al.28 has demonstrated that transfer of CD3+ T cells is detri-
mental for cerebral ischemia and T cells critically contribute to
cerebral ischemia; however, the role of regulatory T cells has been
a controversial concept in the stroke field for a decade29. B cells
are documented protective in acute stroke30. Although we
determined that the BR therapy substantially decreased neu-
trophils in blood (Fig. 4c, d) and brains (Fig. 6) of stroke mice, we
demonstrated that the removal of blood from recipient stroke
mice is essential to develop this therapeutic strategy (Supple-
mentary Fig. 4), which may help release of inflammatory cells
from blood. We argue that the BR therapy could change leukocyte
trafficking and migration into brains when the BBB is closed. For
example, macrophages/monocytes were not significantly changed
in the peripheral blood (Fig. 4c, e) but BR therapy substantially
decreased macrophages/monocytes in stroke brains; B cells were
significantly increased in the peripheral blood by the BR therapy
(Fig. 4i, j) but very few B cells were detected in ischemic brains. It
is important to determine specific roles of white blood cell subsets
by BR therapy administration following a stroke to optimize
therapeutic strategies in the future.
It has been confirmed that MMP-9 is a key proteinase asso-
ciated with BBB leakage, extracellular matrix degradation, and
evolution of cerebral ischemia7. Opening of the BBB is transient
following a stroke3. Compromised BBB integrity allows blood
solutes and inflammatory cells to flow into the brain causing
adverse stroke outcomes such as brain edema and neuronal death.
The shorter time the BBB remains open, the less influx of dele-
terious materials enters into the brain. We did observe that the
BBB is protected following the BR therapy in stroke mice (Fig. 1e,
f). Decreased level of MMP-9 in the periphery and CNS (Fig. 7)
could be one important mechanism in closing the BBB by BR
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Fig. 8 MMP-9 diminished the therapeutic effects of the blood replacement in stroke mice. a Experimental design. Mice (8-month-old males) underwent
tMCAO for 60min. The occlusion and reperfusion were confirmed by a laser speckle imager (LSI). Mice were randomized into three groups: the first group
is the stroke group received tMCAO, the second group is the blood replacement (BR) group receiving 250 µl of blood with vehicle and blood withdrawal,
and the third group is the BR group receiving 250 µl of blood treated with activated MMP-9 (5 µg ml−1) and blood withdrawal. b Quantification of infarct
volumes in the cortex, striatum, and total hemisphere. MMP-9-treated blood did not significantly reduce the infarct volume. Stroke group (circles, n= 6),
stroke with vehicle-treated BR group (triangles, n= 8), and stroke with MMP-9-treated BR group (squares, n= 6). c Representative TTC-stained coronal
brain sections used for infarction analyses. d Neurological deficits were not significantly improved in the BR group with MMP-9-treated blood. Stroke group
(circles, n= 8), stroke with vehicle-treated BR group (triangles, n= 8), and stroke with MMP-9-treated BR group (squares, n= 8). Data were presented as
means ± SEM. One-way ANOVA followed by post hoc Tukey’s multiple comparison tests. Source data are provided as a Source Data file.
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therapy for stroke. We have recently demonstrated a mitochon-
drial mechanism in BBB opening following a stroke31–33. Due to
the analyses of physiological parameters demonstrated that BR
therapy did not change PO2, PCO2, and glucose level in recipient
stroke mice (Supplementary Table 1), our data do not support the
possibility that BR therapy rescues ischemic brains by changing
the physiological parameters. However, it is possible that blood
provides nutrition and protective factors that can help cere-
brovascular endothelial cells restore mitochondrial function and
seal BBB tight junctions following a stroke.
It is known that inflammatory cytokines and chemokines play
a harmful role in acute stroke34. We observed significantly higher
levels of proinflammatory cytokines IL-1β, IL-6, and TNF-α in
plasma of stroke mice and the BR therapy decreased the levels of
these cytokines in plasma (Fig. 5). As active MMP-9 cleaves a
variety of chemokines8 and cytokines9–11, and triggers signaling
through various transmembrane proteins35, the BR therapy might
reduce the cascade inflammatory responses in stroke through
reduced levels of MMP-9 in blood (Fig. 7). It is noted that che-
mokine CXCL1, a neutrophil-activating protein, is substantially
increased in stroke and significantly reduced by the BR therapy at
an early time point post stroke. The cellular source of CXCL1 is
not clear; however, the elevated CXCL1 may explain that neu-
trophils are the first responders that react to acute ischemia36 and
CXCL1 may account for the rise of neutrophils in the blood and
brains following a stroke.
Others have demonstrated that knockout of MMP-9 or inhibi-
tion of MMP-9 can be of therapeutic importance in ischemic
stroke37. It has been shown that MMP-9 inhibitors DP-b9938, KB-
R778539, SB-3CT40, and BB-9437 protect stroke outcomes. Even
though BR therapy profoundly protects stroke outcomes, addition
of MMP-9 to the blood diminishes the protective effect of the BR
therapy and substantially worsens stroke outcomes (Fig. 8). These
data elucidate an MMP-9-involved mechanism in the BR therapy
in stroke and also suggest the importance of measuring the level of
MMP-9 in donor blood for transfusion. The dose of MMP-9
administrated is 1.25 µg 30 g−1 mouse, relative to 500 ngml−1
MMP-9 in blood of recipient mice. This level corresponds to
doubled levels of MMP-9 in blood following a stroke (Fig. 7a). It is
reported that higher plasma levels of pro-MMP-9 early in stroke
are correlated with larger infarct volumes41. We did observe that
longer occlusion causes worse stroke outcomes and more proin-
flammatory responses in early stroke. Permanent stroke causes
more profound inflammatory responses and higher levels of
MMP-9 in blood. Therefore, blood obtained from permanent
stroke mice donors worsened stroke outcomes and caused a high
mortality in stroke mice (Supplementary Fig. 5).
Sex differences exist in response to stroke42–45 and age is
another factor that affects stroke outcomes46. It is not clear
whether blood obtained from different sexes and ages contributes
to different outcomes in stroke. We used blood obtained from
relatively young mice (3~6 months old) and transfused the whole
blood into older stroke mice (8~12 months old) in the study. Our
ongoing study will further address the role of blood obtained
from a wide range of ages of both males and females.
Currently, blood-based therapies are emerging as treatments to
combat aging and fight neurodegenerative diseases47. It is not
likely that the complex pathological changes following a stroke
can be treated by any known, single medication. The proposed BR
therapy offers a strategy that targets the pathological systemic
responses to stroke. The results of this study could lead to a
breakthrough in stroke therapy, because this innovative ther-
apeutic strategy may reduce the mortality of stroke patients and
improve stroke outcomes. These results can provide a foundation
for the future use of BR therapy in clinical trials for improved
treatment of strokes.
Methods
Study approval. The ARRIVE guidelines were followed and Institutional Animal
Care and Use Committee at West Virginia University (WVU) approved criteria for
procedures prior to experimentation.
Animals: We used male 8~12 months old C57/BL6J mice (above 30 g; Jackson’s
Laboratory, ME) for recipients and male 3~6 months old C57/BL6J mice for blood
donors. We used 333 mice for the study. We numbered the animals and allocated
them into groups using a simple randomization of excel-generated random
numbers. To avoid biases, we also assured that different treatments were performed
on the same day.
Murine focal cerebral ischemia model. We anesthetized mice with 4–5% iso-
flurane and maintained anesthesia such that animals did not respond to toe pinch
with 1–2% isoflurane via face mask in oxygen-enriched air. We induced focal
cerebral ischemia by occlusion of the right middle cerebral artery for 90 min with a
6.0 monofilament suture (Doccol, Sharon, MA) and maintained a rectal body
temperature of 37 ± 0.5 °C throughout the surgery. We confirmed a successful
occlusion by changes of regional cerebral blood flow using Laser Speckle Imager
(Moor Instruments, UK) and applied a local analgesia (bupivacaine 1 mg kg−1,
subcutaneously (s.c.)) after stroke surgeries.
Preparation of blood for transfusion. We prepared fresh blood obtained from
naive donors or stroke mice via cardiac puncture while animals were under deep
anesthesia. We collected blood in a syringe containing citrate-phosphate-dextrose
(CPD) buffer (150 µl ml−1 blood) and rapidly mixed with anti-coagulated CPD
buffer for transfusion. Recombinant mouse MMP-9 protein (R&D, USA) was
activated in buffer (50 mM Tris, 10 mM CaCl2, 150 mM NaCl, 0.05% Brij-35, pH
7.5) with 1 mM p-aminophenylmercuric acetate for 2 h then added in fresh pre-
pared blood (5 µg ml−1) for transfusion.
Blood replacement. We conducted all procedures under anesthesia (4–5% iso-
flurane induction and 1–2% isoflurane maintenance). We placed a catheter (pre-
washed with CPD buffer and dried 26 G, MonojectTM, Covidien, Italy) into left
femoral vein for blood transfusion and another catheter (pre-washed with heparin
and dried) was placed into right femoral artery for the blood withdrawal. We
connected a microinjection pump (Genie TouchTM, Lucca Technologies) with the
catheter in the femoral vein with a speed of 20 µl min−1 for blood transfusion. To
withdraw blood, we attached a syringe to the catheter in femoral artery. When the
procedure was completed, we removed the catheters and blotted the incision with
sterilized cotton swabs until cessation of bleeding. We then closed the incisions
with sutures and applied a local analgesia (bupivacaine 1 mg kg−1, s.c.) following
the BR surgeries.
BBB permeability in vivo. We used Evan’s blue extravasation assay to evaluate
BBB permeability in mice. We administered Evan’s blue intravenously through tail
vein 30 minutes prior to euthanization. We transcardially perfused animals with
saline and sectioned brains with a 2 mm coronal brain matrix. We weighed
hemisphere samples and homogenized samples with 400 µL phosphate-buffered
solution (PBS), and then precipitated with 50% trichloroacetic acid (Sigma, CA)
overnight. We centrifuged all samples were 300 × g for 30 min to separate out the
brain tissue in pellet prior to measuring. We quantified Evans blue in the brain by
absorption at 610 nm with a plate reader (BioTek, Winooski, VT). Final results
were quantified as Evans blue microgram/gram brain tissue.
Exclusion criteria. We excluded animals according to the criteria below: (1)
regional cerebral blood flow decreases <70% during occlusion as detected by Laser
Speckle Imager; (2) surgical procedures last more than 30 min; (3) no neurological
deficits at 3 h post-tMCAO; (4) invisible infarction in the MCA territory by TTC
staining; (5) postmortem examination shows subarachnoid hemorrhage; and (6)
substantial ambient temperature changes in the facility. Animals that died prior to
the planned time of assessments were postmortem examined for subarachnoid
hemorrhage and the mortality was recorded. In this study, five mice were excluded:
three mice (one mouse in sham BR control group and two mice in BR group of
blood obtained from stroke mice) because of subarachnoid hemorrhage, two mice
(prior to group randomization), because the Laser Speckle Imager did not detect
70% reduction of CBF after MCAO. The experimenters were blinded to the
treatments for data collection and analysis.
Brain histology. We cut brains in 2 mm brain coronal matrix and stained resulting
sections with 2% TTC (Sigma, Saint Louis, MO) in PBS at 37 °C for 30 min. We
photographed brains using a photo scanner and fixed the tissues in 10% formalin
for 1 week. We used four sections of seen images for data qualification. We ana-
lyzed infarct volumes within the cortex, striatum, and total hemisphere using NIH
Image J software.
We embedded fixed brain sections in paraffin and cut coronal slices (10 µm)
through the brain hippocampus area. We performed Cresyl Violet (Sigma, Saint
Louis, MO), H&E (Sigma, Saint Louis, MO), TUNEL staining (TUNEL Assay Kit -
HRP-DAB, Abcam, Cambridge, MA), and Fluoro-Jade C staining (Sigma, Saint
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Louis, MO) on slides following the manufacturers’ instructions. We took bright
field images for Cresyl Violet, H&E, TUNEL staining, and fluorescent field images
for Fuoro Jade C staining through a slide scanner (Olympus VS120, Japan) at the
Microscope Imaging Facility at WVU.
Neurological deficits. We measured neurological functioning on a 0–5 scale,
where 0= no neurological dysfunction; 1= failure to extend contralateral forelimb
when lifted by tail; 2= circling to the contralateral side; 3= falling to the con-
tralateral side; 4= nonspontaneous walk or in a comatose state; 5= death.
Flow cytometry. We lysed red blood cells in blood by red blood cell lysis buffer
(eBioscience) and isolated leukocytes in brains by 37–70% Percoll (GE Healthcare)
density gradient centrifugation. We counted cell numbers by a Coulter counter
(Thermo Fisher). Cells were washed with buffer (PBS with 0.5% bovine serum
abumin and 0.02% sodium azide) for three times and stained with antibodies listed
in Supplementary Table 2. We used BD FACS LSRFortesa (12 fluorochromes,
three-laser system, BD Biosciences) with FACS Diva version 8.0 software (BD
Biosciences) to determine the phenotypes of leukocytes. We excluded dead cells by
propidium iodide (Sigma, 20 µg ml−1 in PBS) positive staining and analyzed the
data using Flowjo version 10 software (TreeStar).
Electrochemiluminescence assay for cytokines and chemokines. We used an
electrochemiluminescence assay to detect a proinflammatory panel by multiplex
kits obtained from Meso Scale Discovery (Rockville, MD). The kits included
individual assay for quantification of IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-
12, and TNF-α, and the chemokine CXCL1. We followed the manufacturer’s
protocol for evaluation of plasma samples. We read the results on MSD multi-array
imaging platform. We carried out the data analyses using the MSD discovery
workbench software.
ELISA for detection of MMP-9. We obtained murine MMP-9 detection kits from
R&D System and analyzed levels of total MMP-9 in plasma and brains followed the
manufacturer’s instructions. We recorded the results by a Biotek Synergy H1
Hybrid plate reader (wavelength= 450 nm).
Statistical analyses. We conducted statistical analyses with PRISM 7 software
(GraphPad Software, La Jolla, CA). One-way analysis of variance followed by post
hoc test was used for the analysis of data above two groups. The Brown–Forsythe
test was performed for equal population variances among multiple comparisons.
Student’s t-test was used for the analysis of data between two groups. G*Power
v.3.1.9.2 was used to decide power for the animal study. Fisher’s exact test was used
to determine the difference of mortality between groups. All measurements were
taken from distinct samples. Statistical significance was set at p < 0.05 (two-sided).
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Source data are provided as a Source Data file with this paper. The data that support the
findings of this study are available from the corresponding author (X.R.) upon reasonable
request. Source data are provided with this paper.
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